PMA device
Tula® System
Tusker Medical, Inc. · Tympanostomy Tube Delivery Product With Drug (QJA, Class III) · First FDA decision Nov 25, 2019, newest Jan 31, 2025
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
Breakthrough-designated
Device trials
4
Naming "Tula"
MAUDE reports
29
Brand "Tula", since 2015
PubMed studies
425
Mentioning "Tula"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Tula® System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- Tula® SystemPMA supplement
P190016-S009 · Decided Jan 31, 2025 · 177 days after receipt · Normal 180 Day Track No User Fee
Device type: Tympanostomy tube delivery product with drug (QJA) · Otolaryngology (ENT)
- Tula SystemPMA supplement
P190016-S008 · Decided Dec 22, 2023 · 175 days after receipt · Normal 180 Day Track No User Fee
Device type: Tympanostomy tube delivery product with drug (QJA) · Otolaryngology (ENT)
- Tula® SystemPMA supplement
P190016-S007 · Decided Feb 1, 2024 · 302 days after receipt · Normal 180 Day Track
Device type: Tympanostomy tube delivery product with drug (QJA) · Otolaryngology (ENT)
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Tula", any status and sponsor, newest update first.
- inVENT-In-Office StudyCompleted
Integra LifeSciences CorporationPublic (IART)
NCT01324271 · 85 participants · Start Jan 2011 · Primary completion May 2012
Device: Acclarent Tympanostomy Tube Delivery system (TTDS) · For: Otitis Media
Sites: San Antonio, Texas
Integra LifeSciences CorporationPublic (IART)
NCT01496287 · 70 participants · Start Dec 2011 · Primary completion Apr 2012
Device: Tube Delivery System (TDS) · For: Otitis Media
Sites: Port Saint Lucie, Florida
Tusker MedicalNot on our public-company list
NCT03323736 · 370 participants · Start Oct 31, 2017 · Primary completion Feb 28, 2019
Device: Tube placement · For: OME - Otitis Media With Effusion; AOM - Acute Otitis Media
Sites: Carlsbad, California; Roseville, California; San Jose, California · 19 sites in all
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Tula", and for the whole product code for context.
This brand
29 reports: 9 malfunction, 20 injury, 0 death
Whole product code QJA
33 reports: 9 malfunction, 24 injury, 0 death
Newest reports for this brand
- TULA KIT- BILATERAL (NST007069)Malfunction
3012130335-2026-00002 · Received Jul 14, 2026 · Event dated Jun 17, 2026
Device type: Tympanostomy Tube Delivery Product With Drug (QJA)
Device problem as coded: Inadequacy of Device Shape and/or Size
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- TULA KIT- BILATERAL (NST007069)Malfunction
3012130335-2026-00001 · Received Jun 10, 2026 · Event dated May 13, 2026
Device type: Tympanostomy Tube Delivery Product With Drug (QJA)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3012130335-2025-00006 · Received Oct 31, 2025 · Event dated Oct 8, 2025
Device type: Tympanostomy Tube Delivery Product With Drug (QJA)
Device problem as coded: Premature Activation
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Tula"[tiab]. The summary above synthesizes these.
- TULA-Family Regulators of Platelet Activation.
Kunapuli SP, Tsygankov AY · Int J Mol Sci · 2022Review
- TULA proteins as signaling regulators.
Tsygankov AY · Cell Signal · 2020Review
- Role of Tula-Family Proteins in Cell Signaling and Activation: Advances and Challenges.
Tsygankov AY · Int J Mol Sci · 2024Editorial, Introductory Journal Article
- TULA Proteins in Men, Mice, Hens, and Lice: Welcome to the Family.
Tsygankov AY · Int J Mol Sci · 2023Review
- TULA-family proteins: Jacks of many trades and then some.
Tsygankov AY · J Cell Physiol · 2018Review
- TULA-family proteins: an odd couple.
Tsygankov AY · Cell Mol Life Sci · 2009Review
- Tula hantavirus in Belgium.
Heyman P, Klingström J, de Jaegere F, et al. · Epidemiol Infect · 2002Research Support, Non-U.S. Gov't
- Tula Virus as Causative Agent of Hantavirus Disease in Immunocompetent Person, Germany.
Hofmann J, Kramer S, Herrlinger KR, et al. · Emerg Infect Dis · 2021Research Support, Non-U.S. Gov't
- High genetic structuring of Tula hantavirus.
Schmidt S, Saxenhofer M, Drewes S, et al. · Arch Virol · 2016Research Support, Non-U.S. Gov't
- TULA-family proteins: a new class of cellular regulators.
Tsygankov AY · J Cell Physiol · 2013Review
- TULA DUAL: Trans Urethral Laser Ablation of recurrent bladder tumors in outpatient setting.
Leonardi R, Vecco F, Iacona G, et al. · Arch Ital Urol Androl · 2023
- Roles of TULA-family proteins in T cells and autoimmune diseases.
Wang H, Concannon P, Ge Y · Genes Immun · 2025Review, Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.